Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD
Experimental and Clinical Endocrinology & Diabetes · 01.11.2023 · 131 (11) · 583-588
DOI: 10.1055/a-2145-1004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.11.2023. Verfasst von Lin Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Guidance Project of Shanghai Science and Technology Commission, Science and Technology Commission of Shanghai Municipality, Scientific Research and Development Foundation of Zhongshan Hospital, Fudan University.
Abstract (Originalsprache)
Aim
This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
Methods
We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm2) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra.
Results
There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (–215.52, 280.80) mm2 in the insulin glargine group and decrease by 149.09 (322.90–56.39) mm2 in the exenatide group (both p>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm2) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
- Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China.
- School of Kinesiology, Shanghai University of Sport, Shanghai, China.
- Department of Nutrition, Zhongshan Hospital, Fudan University.
- Center of Clinical Epidemiology and Evidence-based Medicine, Fudan University.
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Förderung
- Medical Guidance Project of Shanghai Science and Technology Commission
- Science and Technology Commission of Shanghai Municipality
- Scientific Research and Development Foundation of Zhongshan Hospital, Fudan University
Zitieren
APA
Liu, L., Wang, R., Gao, J., Yan, J., Zhang, J., Zhang, Z., Liu, J., Lin, H., Rao, S., Yao, X., Wu, W., Bian, H., Wang, X., Guo, S., Gao, X., & Yan, H. (2023). Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD. Experimental and Clinical Endocrinology & Diabetes, 131(11), 583-588. https://doi.org/10.1055/a-2145-1004
Vancouver
Liu L, Wang R, Gao J, Yan J, Zhang J, Zhang Z, et al. Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD. Experimental and Clinical Endocrinology & Diabetes. 2023;131(11):583-588. doi:10.1055/a-2145-1004
BibTeX
@article{Liu2023,
author = {Liu, Lin and Wang, Ruwen and Gao, Jian and Yan, Jianhua and Zhang, Jingtian and Zhang, Zhitian and Liu, Jiaojiao and Lin, Huandong and Rao, Shengxiang and Yao, Xiuzhong and Wu, Weiyun and Bian, Hua and Wang, Xiangyu and Guo, Shanshan and Gao, Xin and Yan, Hongmei},
title = {Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {11},
pages = {583--588},
doi = {10.1055/a-2145-1004}
}
EUVIMED